Comparative Pharmacology
Head-to-head clinical analysis: FLUOR OP versus INFLAMASE FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUOR OP versus INFLAMASE FORTE.
FLUOR-OP vs INFLAMASE FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorometholone is a corticosteroid that inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis, thereby suppressing inflammatory responses.
Inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
2 drops of 0.1% solution into the affected eye(s) every 15 minutes for 4 doses, then every 30 minutes for 2 doses, then every 1-2 hours for 24-48 hours, then tapering over 1-2 weeks; alternatively, 0.5 cm ribbon of 0.05% ointment into the conjunctival sac 4-6 times daily.
1-2 tablets (ibuprofen 400mg / pseudoephedrine 60mg) orally every 6 hours as needed; maximum 6 tablets per day.
None Documented
None Documented
Terminal elimination half-life is 3-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Terminal half-life 36–42 hours in patients with normal renal function; prolonged to 18–26 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal excretion of unchanged drug accounts for approximately 60-80% of elimination, with the remainder as metabolites (glucuronide conjugates) via urine; fecal elimination is minimal (<5%).
Approximately 95% renal: 90% as unchanged drug via glomerular filtration and tubular secretion, 5% as minor metabolites; 5% fecal via biliary elimination.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid